RANI vs. TERN, MREO, ERAS, HROW, NATR, ADCT, AMRN, ANRO, PGEN, and ATAI
Should you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Terns Pharmaceuticals (TERN), Mereo BioPharma Group (MREO), Erasca (ERAS), Harrow (HROW), Nature's Sunshine Products (NATR), ADC Therapeutics (ADCT), Amarin (AMRN), Alto Neuroscience (ANRO), Precigen (PGEN), and Atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical preparations" industry.
Terns Pharmaceuticals (NASDAQ:TERN) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.
Terns Pharmaceuticals received 12 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 76.67% of users gave Rani Therapeutics an outperform vote while only 58.33% of users gave Terns Pharmaceuticals an outperform vote.
In the previous week, Terns Pharmaceuticals had 7 more articles in the media than Rani Therapeutics. MarketBeat recorded 15 mentions for Terns Pharmaceuticals and 8 mentions for Rani Therapeutics. Terns Pharmaceuticals' average media sentiment score of 0.85 beat Rani Therapeutics' score of 0.51 indicating that Rani Therapeutics is being referred to more favorably in the news media.
Rani Therapeutics has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.
Terns Pharmaceuticals has a beta of -0.49, meaning that its stock price is 149% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.
Terns Pharmaceuticals presently has a consensus target price of $14.94, suggesting a potential upside of 153.18%. Rani Therapeutics has a consensus target price of $12.20, suggesting a potential upside of 133.72%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Terns Pharmaceuticals is more favorable than Rani Therapeutics.
Rani Therapeutics' return on equity of -35.54% beat Terns Pharmaceuticals' return on equity.
98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 17.4% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 53.3% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Terns Pharmaceuticals and Rani Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Rani Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rani Therapeutics Competitors List
Related Companies and Tools
